SNAI2 and ovarian cancer: This is achieved through different pathways such as increasing the expression of miR-219-5p in hepatocellular carcinoma cells [11], upregulating miR-124-3p.1 and downregulating AKT3 in colorectal cancer [12], suppressing the transcription factor slug in ovarian cancer cells [76], or modulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cells [77].